The effects of PACAP and PACAP antagonist on the neurobehavioral development of newborn rats

Behavioural Brain Research

Volumn 140, Issue 1-2, 2003, Pages 131-139

  Reglödi, Dóra ^a   Kiss, Péter ^a   Tamás, Andrea ^a   Lengvári, István ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Exploratory behavior; Neurobehavioral development; PACAP; Rat

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXPLORATORY BEHAVIOR; FACE DEVELOPMENT; MOTOR ACTIVITY; NEWBORN; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; RIGHTING REFLEX; SENSORY SYSTEM;

ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; EXPLORATORY BEHAVIOR; GAIT; NEUROPEPTIDES; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PSYCHOMOTOR PERFORMANCE; RATS; RATS, WISTAR; REFLEX;

EID: 17144462039     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(02)00289-9     Document Type: Article

References (60)

1. Altman J., Sudarshan K. Postnatal development of locomotion in the laboratory rat. Anim. Behav. 23:1975;896-920.
2. Arimura A. Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine and nervous systems. Jpn. J. Physiol. 48:1998;301-331.
3. Basille M., Gonzalez B.J., Fournier A., Vaudry H. Ontogeny of pituitary adenylate cyclase activating polypeptide (PACAP) receptors in the rat cerebellum: a quantitative autoradiographic study. Dev. Brain Res. 82:1994;81-89.
4. 1A receptor in development of the neonatal rat brain: preliminary behavioral studies. Neuropharmacology. 36:1997;445-450.
5. Bures J., Buresova O., Huston J.P. Techniques and basic experiments for the study of brain and behavior. 1983;77-97 Elsevier, Amsterdam.
6. Campard P.K., Crochemore C., Rene F., Monnier D., Koch B., Loeffler J.P. PACAP type I receptor activation promotes cerebellar neuron survival through the cAMP/PKA signaling pathway. DNA Cell Biol. 16:1997;323-333.
7. Chance W.T., Thompson H., Thomas I., Fischer J.E. Anorectic and neurochemical effects of pituitary adenylate cyclase activating polypeptide in rats. Peptides. 16:1995;1511-1516.
8. Chang E., Welch S., Luna J., Giacalone J., Francke U. Generation of a human chromosome 18-specific YAC clone collection and mapping of 55 unique YACs by FISH and fingerprinting. Genomics. 17:1993;393-402.
9. Cirulli F., Alleva E. Effects of repeated administration of EGF and FGF-alpha on mouse neurobehavioral development. Neurotoxicology. 15:1994;819-825.
10. Dam K., Seidler F.J., Slotkin T.A. Chlorpyrifos exposure during a critical neonatal period elicits gender-selective deficits in the development of coordination skills and locomotor activity. Dev. Brain Res. 121:2000;179-187.
11. DeZazzo J., Xia S., Chriestensen J., Velinzon K., Tully T. Development expression of an amn+transgene rescues the mutant memory defect of amnesic adults. J. Neurosci. 19:1999;8740-8746.
12. Dobbing J., Sands J. Quantitative growth and development of human brain. Arch. Dis. Child. 48:1973;757-767.
13. Erhardt N.M., Fradinger E.A., Cervini L.A., Rivier J.E., Sherwood N.M. Early expression of pituitary adenylate cyclase activating polypeptide and activation of its receptor in chick neuroblasts. Endocrinology. 142:2001;1616-1625.
14. Fernandez B., Romero E.M., Kitchen I., Viveros M.P. Postnatal naltrindole treatments induce behavioral modifications in preweanling rats. Neurosci. Lett. 283:2000;73-76.
15. Frechilla D., Garcia-Osta A., Palacios S., Cenarruzabietia E., Del Rio J. BDNF mediates the neuroprotective effect of PACAP38 on rat cortical neurons. Neuroreport. 12:2001;919-923.
16. Garcia-Arraras J.E., Chanconie M., Ziller C., Fauquet M. In vivo and in vitro expression of vasoactive intestinal polypeptide-like immunoreactivity by neural crest derivatives. Dev. Brain Res. 33:1987;255-265.
17. Gloddek J., Pagotto U., Paez Pereda M., Arzt E., Stalla G.K., Renner U. Pituitary adenylate cyclase activating polypeptide, interleukin-6 and glococorticoids regulate release of vascular endothelial growth factor in pituitary folliculostellate cells. J. Endocrinol. 160:1999;483-490.
18. Gressens P., Hill J.M., Paindaveine B., Gozes I., Fridkin M., Brenneman D.E. Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium in the mouse. J. Clin. Invest. 94:1994;2020-2027.
19. Gressens P., Besse L., Robberecht P., Gozes I., Fridkin M., Evrard P. Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives. J. Pharmacol. Exp. Ther. 288:1999;1207-1213.
20. Hansel D.E., Eipper B.A., Ronnett G.V. Regulation of olfactory neurogenesis by amidated neuropeptides. J. Neurosci. Res. 66:2001;1-7.
21. Hansel D.E., May V., Eipper B.A., Ronnett G.V. Pituitary adenylate cyclase activating peptides and α-amidation in olfactory neurogenesis and neuronal survival in vitro. J. Neurosci. 21:2001;4625-4636.
22. Hashimoto H., Shintani N., Tanaka K., Mori W., Hirose M., Matsuda T., Sakaue M., Miyazaki J., Niwa H., Tashiro F., Yamamoto K., Koga K., Tomimoto S., Kunugi A., Suetake S., Baba A. Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase activating polypeptide (PACAP). Proc. Natl. Acad. Sci. USA. 98:2001;13355-13360.
23. Hill J.M., Gozes I., Hill J.L., Fridkin M., Brenneman D.E. Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. Peptides. 12:1991;187-192.
24. Hosoya M., Kimura C., Ogi K., Ohkubo S., Miyamoto Y., Kugoh H., Shimizu M., Onda H., Oshimura M., Arimura A., Fujino M. Structure of the human pituitary adenylate cyclase activating polypeptide (PACAP) gene. Biochim. Biophys. Acta. 1129:1992;199-206.
25. Hu Z., Lelievre V., Rodriguez W.I., Tam J., Cheng J.W., Chen-Cory S., Waschek J.A. Embryonic expression of pituitary adenylyl cyclase-activating polypeptide and its selective type I receptor gene in the frog Xenopus laevis neural tube. J. Comp. Neurol. 441:2001;266-275.
26. Kovács M., Fáncsik A., Hrabovsky E., Mezo I., Teplán I., Flerkó B. Effects of continuous and repetitive administration of a potent analog of GH-RH(1-30)-NH2 on the GH release in rats treated with monosodium glutamate. J. Neuroendocrinol. 7:1995;703-712.
27. Langman's Medical Embriology, Lippincott Williams and Wilkins, Sadler TW editor. 2000. p. 357-80.
28. Lee M., Lelievre V., Zhao P., Torres M., Rodriguez W., Byun J.Y., Doshi S., Ioffe Y., Gupta G., Monteros A.E., Vellis J., Waschek J. Pituitary adenylate cyclase activating polypeptide stimulates DNA synthesis but delays maturation of oligodendrocyte progenitors. J. Neurosci. 21:2001;3849-3859.
29. Lengvári I. Effect of perinatal monosodium glutamate treatment on endocrine functions of rats in maturity. Acta Biol. Hung. 28:1977;133-141.
30. Lohrer P., Gloddek J., Hopfner U., Losa M., Uhl E., Pagotto U., Stalla G.K., Renner U. Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro. Neuroendocrinology. 74:2001;95-105.
31. Lu N., DiCicco-Bloom E. Pituitary adenylate cyclase activating polypeptide is an autocrine inhibitor of mitosis in cultured cortical precursor cells. Proc. Natl. Acad. Sci. USA. 94:1997;3357-3362.
32. Masuo Y., Noguchi J., Morita S., Matsumoto Y. Effects of intracerebroventricular administration of pituitary adenylate cyclase activating polypeptide (PACAP) on the motor activity and reserpine-induced hypothermia in murines. Brain Res. 700:1995;219-226.
33. Matsumoto S.G. Neuronal differentiation in cultures of murine neural crest. I. Neurotransmitter expression. Dev. Brain Res. 83:1994;1-16.
34. Morley J.E., Horowitz M., Morley P.M.K., Flood J.F. Pituitary adenylate cyclase activating polypeptide (PACAP) reduces food intake in mice. Peptides. 13:1992;1133-1135.
35. Nicot A., DiCicco-Bloom E. Regulation of neuroblast mitosis is determined by PACAP receptor isoform expression. Proc. Natl. Acad. Sci. USA. 98:2001;4758-4763.
36. Nielsen H.S., Hannibal J., Fahrenkrug J. Expression of pituitary adenylate cyclase activating polypeptide (PACAP) in the postnatal and adult rat cerebellar cortex. Neuroreport. 9:1998;2639-2642.
37. Otto C., Kuvalchuk Y., Wolfer D.P., Gass P., Martin M., Zuschratter W., Grone H.J., Kellendonk C., Tronche F., Maldonado R., Lipp H.P., Konnerth A., Schutz G. Impairment of mossy fiber long-term potentiation and associative learning in pituitary adenylate cyclase activating polypeptide type I receptor-deficient mice. J. Neurosci. 21:2001;5520-5527.
38. Otto C., Martin M., Wolfer D.P., Lipp H.P., Maldonado R., Schutz G. Altered emotional behavior in PACAP-type-I-receptor-deficient mice. Mol. Brain Res. 92:2001;78-84.
39. Przywara D.A., Kulkarni J.S., Wakade T.D., Leontiev D.V., Wakade A.R. Pituitary adenylyl cyclase activating polypeptide and nerve growth factor use proteosome to rescue nerve growth factor-deprived sympathetic neurons cultured from chick embryos. J. Neurochem. 71:1998;1889-1897.
40. Puig de Parada M., Parada M.A., Hernandez L. Dipsogenic effect of pituitary adenylate cyclase activating polypeptide (PACAP38) injected into the lateral hypothalamus. Brain Res. 696:1995;254-257.
41. Reglödi D., Somogyvari-Vigh A., Vigh S., Kozicz T., Arimura A. Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke. 31:2000;1411-1417.
42. Risau W., Wolburg H. Development of the blood-brain barrier. Trends Neurosci. 13:1990;174-178.
43. Roth K.A., Katz R.J. Stress, behavioral arousal, and open-field activity - a reexamination of emotionality in the rat. Neurosci. Biobehav. Rev. 3:1979;247-263.
44. Sachetti B., Lorenzini C.A., Baldi E., Bucherelli C., Roberto M., Tassoni G., Brunelli M. Pituitary adenylate cyclase activating polypeptide hormone (PACAP) at very low dosages improves memory in the rat. Neurobiol. Learn. Mem. 76:2001;1-6.
45. Sherwood N.M., Krueckl S.L., McRory J.E. The origin and function of the pituitary adenylate cyclase activating polypeptide (PACAP)/glucagon superfamily. Endocr. Rev. 21:2000;619-670.
46. Sheward W.J., Lutz E.M., Copp A.J., Harmar A.J. Expression of PACAP, and PACAP type 1 (PAC1) receptor mRNA during development of the mouse embryo. Dev. Brain Res. 109:1998;245-253.
47. Skoglosa Y., Takei N., Lindholm D. Distribution of pituitary adenylate cyclase activating polypeptide mRNA in the developing rat brain. Mol. Brain Res. 65:1999;1-13.
48. Smart J.L., Dobbing J. Vulnerability of developing brain. II. Effects of early nutritional deprivation on reflex ontogeny and development on behavior in the rat. Brain Res. 28:1971;85-95.
49. Smart J.L., Dobbing J. Vulnerability of developing brain. VI. Relative effects of foetal and early postnatal undernutrition on reflex ontogeny and development of behavior in the rat. Brain Res. 33:1971;303-314.
50. Sung K.J., Chang S.E., Paik E.M., Lee M.W., Choi J.H. Vasoactive intestinal polypeptide stimulates the proliferation of HaCaT cell via TGF-alpha. Neuropeptides. 33:1999;435-446.
51. Tabuchi A., Koizumi M., Nakatsubo J., Yaguchi T., Tsuda M. Involvement of endogenous PACAP expression in the activity-dependent survival of mouse cerebellar granule cells. Neurosci. Res. 39:2001;85-93.
52. Tamás A., Reglodi D., Szantó Z., Borsiczky B., Németh J., Lengvári I. Comparative neuroprotective effects of preischemic PACAP and VIP administration in permanent occlusion of the middle cerebral artery in rats. Neuroendocrinol. Lett. 23:2002;249-254.
53. Telegdy G., Kokavszky K. The action of pituitary adenylate cyclase activating polypeptide (PACAP) on passive avoidance learning. The role of neurotransmitters. Brain Res. 874:2000;194-199.
54. Uchida D., Arimura A., Somogyvári-Vigh A., Shioda S., Banks W.A. Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide. Brain Res. 736:1996;280-286.
55. Vaudry D., Gonzalez B.J., Basille M., Fournier A., Vaudry H. Neurotrophic activity of pituitary adenylate cyclase activating polypeptide on rat cerebellar cortex during development. Proc. Natl. Acad. Sci. USA. 96:1999;9415-9420.
56. Vaudry D., Gonzalez B.J., Basille M., Yon L., Fournier A., Vaudry H. Pituitary adenylate cyclase activating polypeptide and its receptors: from structure to functions. Pharmacol. Rev. 52:2000;269-324.
57. Vaudry D., Gonzalez B.J., Basille M., Pamantung T.F., Fontaine M., Fournier A. The neuroprotective effect of pituitary adenylate cyclase activating polypeptide on cerebellar granule cells is mediated through inhibition of the CED3-related cystein protease caspase-3/CPP32. Proc. Natl. Acad. Sci. USA. 97:2000;13390-13395.
58. Waschek J.A., Lelievre V., Bravo D.T., Nguyen T., Muller J.M. Retinoic acid regulation of the VIP and PACAP autocrine ligand and receptor system in human neuroblastoma cell lines. Peptides. 18:1997;835-841.
59. Waschek J.A., Casillas R.A., Nguyen T.B., Di-Cicco-Bloom E.M., Carpenter E.M., Rodriguez W.I. Neural tube expression of pituitary adenylate cyclase activating peptide (PACAP) and receptor: potential role in patterning and neurogenesis. Proc. Natl. Acad. Sci. USA. 95:1998;9602-9617.
60. Zupan V., Hill J.M., Brenneman D.E., Gozes I., Fridkin M., Robberecht P., Evrard P., Gressens P. Involvement of pituitary adenylate cyclase activating polypeptide II, vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis. J. Neurochem. 70:1998;2165-2173.